KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Common Equity (2020 - 2025)

Historic Common Equity for Oscar Health (OSCR) over the last 6 years, with Q4 2025 value amounting to $980.7 million.

  • Oscar Health's Common Equity fell 351.13% to $980.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $980.7 million, marking a year-over-year decrease of 351.13%. This contributed to the annual value of $980.7 million for FY2025, which is 351.13% down from last year.
  • Latest data reveals that Oscar Health reported Common Equity of $980.7 million as of Q4 2025, which was down 351.13% from $1.0 billion recorded in Q3 2025.
  • Over the past 5 years, Oscar Health's Common Equity peaked at $1.8 billion during Q1 2021, and registered a low of $806.1 million during Q4 2023.
  • Moreover, its 5-year median value for Common Equity was $1.1 billion (2022), whereas its average is $1.2 billion.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 27294.72% in 2021, then plummeted by 3591.48% in 2022.
  • Over the past 5 years, Oscar Health's Common Equity (Quarter) stood at $1.4 billion in 2021, then tumbled by 35.91% to $892.4 million in 2022, then decreased by 9.67% to $806.1 million in 2023, then rose by 26.09% to $1.0 billion in 2024, then decreased by 3.51% to $980.7 million in 2025.
  • Its Common Equity stands at $980.7 million for Q4 2025, versus $1.0 billion for Q3 2025 and $1.2 billion for Q2 2025.